Hepatitis B and C

作者：Karnsakul Wikrom^*; Schwarz Kathleen B

来源：Pediatric Clinics of North America, 2017, 64(3): 641-+.

DOI：10.1016/j.pcl.2017.01.007

• Hepatitis B
• Hepatitis C
• Sustained virologic response
• Pegylated interferon
• Direct-acting antiviral agents
• Spontaneous viral clearance

Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.

• 出版日期2017-6